1. Pink Sheet
  2. >>Pathways & Standards
  3. >>Approval Standards

US FDA Outlines Streamlined Development Path For Targeted Therapies

 
• By Derrick Gingery

But reminds sponsors that more trials could be ordered post-approval, which may be important in face of evidence that tissue-agnostic cancer therapies are not always equally effective.

T-cells attacking cancer_1200x675

The US FDA has laid out a more definitive pathway for molecularly-targeted drugs seeking indications in multiple patient subsets, but still left open the possibility that additional clinical evidence could be ordered or indications adjusted later should contrary evidence arise.

The new draft guidance outlining development standards for targeted therapies in low-frequency molecular subsets of a disease allows sponsors...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Approval Standards

More from Pathways & Standards

What UK’s Clinical Trials Overhaul Means For Orphan Drug Developers

 
• By Eliza Slawther

The UK government has acknowledged that sponsors of clinical trials for rare diseases face challenges around patient recruitment and trial design, which will be addressed in its clinical trials reform, a lawyer says.

Generic Drug Office’s Policy Staff Returning To US FDA

 
• By Derrick Gingery

The group had been laid off as part of the 1 April reduction-in-force, which led to missed guidance publication deadlines.

Nipah Vaccine With ‘Pandemic Potential’ Wins EMA PRIME Designation

 
• By Neena Brizmohun

The developers of the ChAdOx1 NipahB vaccine will be able to benefit from the early and enhanced support that the European Medicines Agency offers through its priority medicines scheme.